Trial Profile
A multi-center proof-of-concept phase2 study of encorafenib + binimetinib + cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Dec 2018
Price :
$35
*
At a glance
- Drugs Binimetinib (Primary) ; Cetuximab (Primary) ; Encorafenib (Primary)
- Indications Colorectal cancer
- Focus Proof of concept; Therapeutic Use
- Acronyms BIG BANG
- 19 Sep 2018 Status changed from not yet recruiting to recruiting.
- 03 Apr 2018 New trial record